{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:36:40Z","timestamp":1793885800433,"version":"4.8.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/100008308","name":"City of Hope Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["NIH P30CA033572"],"award-info":[{"award-number":["NIH P30CA033572"]}],"id":[{"id":"10.13039\/100008308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008308","name":"City of Hope Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["NIH R01CA166161"],"award-info":[{"award-number":["NIH R01CA166161"]}],"id":[{"id":"10.13039\/100008308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008308","name":"City of Hope Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["R21NS074392"],"award-info":[{"award-number":["R21NS074392"]}],"id":[{"id":"10.13039\/100008308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008308","name":"City of Hope Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["R21AI105057"],"award-info":[{"award-number":["R21AI105057"]}],"id":[{"id":"10.13039\/100008308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008308","name":"City of Hope Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["R01HL112638"],"award-info":[{"award-number":["R01HL112638"]}],"id":[{"id":"10.13039\/100008308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012513","name":"Rotary Coins for Alzheimer\u2019s Research Trust","doi-asserted-by":"publisher","award":["R01 CA172896"],"award-info":[{"award-number":["R01 CA172896"]}],"id":[{"id":"10.13039\/100012513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2023,10,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objective:<\/jats:title>\n                    <jats:p>Disease relapse and therapy resistance remain serious impediments to treating cancer. Leukemia stem cells (LSC) are therapy resistant and the cause of relapse. A state of deep quiescence appears to enable cancer stem cells (CSC) to acquire new somatic mutations essential for disease progression and therapy resistance. Both normal hematopoietic stem cells (HSC) and LSC share many common features, thereby complicating the safe elimination of LSC. A recent study demonstrated that long lived normal oocytes exist without mitochondrial complex I (MC-1), expressing it in a developmentally regulated fashion, thereby mitigating their vulnerability to ROS. Quiescent CSC rely on mitochondrial FAO, without complex I expression, thereby avoiding the generation of damaging ROS, similar to long lived normal human stem cells. A deeper understanding of the biology of therapy resistance is important for the development of optimal strategies to attain complete leukemia cures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Here, using scRNA-sequencing and ATAC-seq on primary chronic myelogenous leukemia (CML) patient samples, combined with bioinformatics analyses, we further examine the heterogeneity of a previously characterized in vitro imatinib-selected CD34-CD38- CML LSC population. We utilized a series of functional analyses, including single-cell metabolomic and Seahorse analyses, to validate the existence of the deepest quiescent leukemia initiators (LI) subset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Current study revealed heterogeneity of therapy resistant LSC in CML patients and their existence of two functionally distinct states. The most deeply quiescent LI suppress the expression of MC-1, yet are highly dependent on fatty acid oxidation (FAO) for their metabolic requirements and ATAC-seq demonstrated increased chromatin accessibility in this population, all consistent with an extremely primitive, quiescent stemness transcriptional signature. Importantly, the specific CREB binding protein (CBP)\/\u03b2-catenin antagonist ICG-001 initiates the differentiation of LSC, including LI, decreases chromatin accessibility with differentiation and increasing expression of MC-1, CD34, CD38 and BCR-ABL1, thereby re-sensitizing them to imatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We investigated the biological aspects related to LSC heterogeneity in CML patients and demonstrated the ability of specific small molecule CBP\/\u03b2-catenin antagonists to safely eliminate deeply quiescent therapy resistant CSC. These observations may represent an attractive generalizable therapeutic strategy that could help develop better protocols to eradicate the quiescent LSC population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1874467217666230906092236","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:23:21Z","timestamp":1694391801000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious\nROS by Suppressing Mitochondrial Complex I"],"prefix":"10.1016","volume":"17","author":[{"given":"Nyam-Osor","family":"Chimge","sequence":"first","affiliation":[{"name":"Department of Cancer Biology and Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hsuan","family":"Chen","sequence":"additional","affiliation":[{"name":"The Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cu","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Wu","sequence":"additional","affiliation":[{"name":"2The Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina Garcia","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Aix Marseille University, CNRS, INSERM, CIML, Centre d\u2019Immunologie de Marseille-Luminy, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Ogana","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood and Bone Marrow Transplantation, Children\u2019s Hospital Los Angeles, Los Angeles, CA 90027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood and Bone Marrow Transplantation, Children\u2019s Hospital Los Angeles, Los Angeles, CA 90027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ling","family":"Teo","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine Research, Children\u2019s National Hospital. Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"The Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jin","sequence":"additional","affiliation":[{"name":"Institute of Health Equity and MCW Cancer Center, The Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Mi","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood and Bone Marrow Transplantation, Children\u2019s Hospital Los Angeles, Los Angeles, CA 90027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Clinical Proteomics, National Cancer Center Research Institute, Tokyo 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael J.","family":"Arg\u00fcello","sequence":"additional","affiliation":[{"name":"Aix Marseille University, CNRS, INSERM, CIML, Centre d\u2019Immunologie de Marseille-Luminy, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA | City of Hope, Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.12.002","volume":"35","author":"Giles F.J.","year":"2008","unstructured":"Giles F.J.; DeAngelo D.J.; Baccarani M.; Deininger M.; Guilhot F.; Hughes T.; Mauro M.; Radich J.; Ottmann O.; Cortes J.; Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol  2008,35(1),S1-S17","journal-title":"Semin Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"Mahon F.X.","year":"2010","unstructured":"Mahon F.X.; R\u00e9a D.; Guilhot J.; Guilhot F.; Huguet F.; Nicolini F.; Legros L.; Charbonnier A.; Guerci A.; Varet B.; Etienne G.; Reiffers J.; Rousselot P.; Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol  2010,11(11),1029-1035","journal-title":"Lancet Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"Ross D.M.","year":"2013","unstructured":"Ross D.M.; Branford S.; Seymour J.F.; Schwarer A.P.; Arthur C.; Yeung D.T.; Dang P.; Goyne J.M.; Slader C.; Filshie R.J.; Mills A.K.; Melo J.V.; White D.L.; Grigg A.P.; Hughes T.P.; Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood  2013,122(4),515-522","journal-title":"Blood"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"Saussele S.","year":"2018","unstructured":"Saussele S.; Richter J.; Guilhot J.; Gruber F.X.; Hjorth-Hansen H.; Almeida A.; Janssen J.J.W.M.; Mayer J.; Koskenvesa P.; Panayiotidis P.; Olsson-Str\u00f6mberg U.; Martinez-Lopez J.; Rousselot P.; Vestergaard H.; Ehrencrona H.; Kairisto V.; Machov\u00e1 Pol\u00e1kov\u00e1 K.; M\u00fcller M.C.; Mustjoki S.; Berger M.G.; Fabarius A.; Hofmann W.K.; Hochhaus A.; Pfirrmann M.; Mahon F.X.; Ossenkoppele G.; Pagoni M.N.; S\u00f6derlund S.; Escoffre-Barbe M.; Etienne G.; Dengler J.; Huguet F.; von Bubnoff N.; Klamova H.; Faber E.; Guilhot F.; Lotfi K.; Rea D.; Br\u00fcmmendorf T.H.; de Greef G.E.; Stenke L.; Nicolini F.E.; Legros L.; Burchert A.; Voglova J.; Charbonnier A.; Gyan E.; Kunzmann V.; Westerweel P.E.; Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol  2018,19(6),747-757","journal-title":"Lancet Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"Shah N.P.","year":"2020","unstructured":"Shah N.P.; Garc\u00eda-Guti\u00e9rrez V.; Jim\u00e9nez-Velasco A.; Larson S.; Saussele S.; Rea D.; Mahon F.X.; Levy M.Y.; G\u00f3mez-Casares M.T.; Pane F.; Nicolini F.E.; Mauro M.J.; Sy O.; Martin-Regueira P.; Lipton J.H.; Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study. Leuk Lymphoma  2020,61(3),650-659","journal-title":"Leuk Lymphoma"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"Holyoake T.L.","year":"2017","unstructured":"Holyoake T.L.; Vetrie D.; The chronic myeloid leukemia stem cell: Stemming the tide of persistence. Blood  2017,129(12),1595-1606","journal-title":"Blood"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"Bolton-Gillespie E.","year":"2013","unstructured":"Bolton-Gillespie E.; Schemionek M.; Klein H.U.; Flis S.; Hoser G.; Lange T.; Nieborowska-Skorska M.; Maier J.; Kerstiens L.; Koptyra M.; M\u00fcller M.C.; Modi H.; Stoklosa T.; Seferynska I.; Bhatia R.; Holyoake T.L.; Koschmieder S.; Skorski T.; Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood  2013,121(20),4175-4183","journal-title":"Blood"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"Vetrie D.","year":"2020","unstructured":"Vetrie D.; Helgason G.V.; Copland M.; The leukaemia stem cell: Similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer  2020,20(3),158-173","journal-title":"Nat Rev Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"Jamieson C.H.M.","year":"2004","unstructured":"Jamieson C.H.M.; Ailles L.E.; Dylla S.J.; Muijtjens M.; Jones C.; Zehnder J.L.; Gotlib J.; Li K.; Manz M.G.; Keating A.; Sawyers C.L.; Weissman I.L.; Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med  2004,351(7),657-667","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","volume":"114","author":"Lemoli R.M.","year":"2009","unstructured":"Lemoli R.M.; Salvestrini V.; Bianchi E.; Bertolini F.; Fogli M.; Amabile M.; Tafuri A.; Salati S.; Zini R.; Testoni N.; Rabascio C.; Rossi L.; Martin-Padura I.; Castagnetti F.; Marighetti P.; Martinelli G.; Baccarani M.; Ferrari S.; Manfredini R.; Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood  2009,114(25),5191-5200","journal-title":"Blood"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"Ng S.W.K.","year":"2016","unstructured":"Ng S.W.K.; Mitchell A.; Kennedy J.A.; Chen W.C.; McLeod J.; Ibrahimova N.; Arruda A.; Popescu A.; Gupta V.; Schimmer A.D.; Schuh A.C.; Yee K.W.; Bullinger L.; Herold T.; G\u00f6rlich D.; B\u00fcchner T.; Hiddemann W.; Berdel W.E.; W\u00f6rmann B.; Cheok M.; Preudhomme C.; Dombret H.; Metzeler K.; Buske C.; L\u00f6wenberg B.; Valk P.J.M.; Zandstra P.W.; Minden M.D.; Dick J.E.; Wang J.C.Y.; A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature  2016,540(7633),433-437","journal-title":"Nature"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1084\/jem.20151775","volume":"213","author":"Quek L.","year":"2016","unstructured":"Quek L.; Otto G.W.; Garnett C.; Lhermitte L.; Karamitros D.; Stoilova B.; Lau I.J.; Doondeea J.; Usukhbayar B.; Kennedy A.; Metzner M.; Goardon N.; Ivey A.; Allen C.; Gale R.; Davies B.; Sternberg A.; Killick S.; Hunter H.; Cahalin P.; Price A.; Carr A.; Griffiths M.; Virgo P.; Mackinnon S.; Grimwade D.; Freeman S.; Russell N.; Craddock C.; Mead A.; Peniket A.; Porcher C.; Vyas P.; Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med  2016,213(8),1513-1535","journal-title":"J Exp Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2009-02-206565","volume":"115","author":"Taussig D.C.","year":"2010","unstructured":"Taussig D.C.; Vargaftig J.; Miraki-Moud F.; Griessinger E.; Sharrock K.; Luke T.; Lillington D.; Oakervee H.; Cavenagh J.; Agrawal S.G.; Lister T.A.; Gribben J.G.; Bonnet D.; Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction. Blood  2010,115(10),1976-1984","journal-title":"Blood"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1874467210666170919155739","volume":"11","author":"Zhao Y.","year":"2018","unstructured":"Zhao Y.; Wu K.; Wu Y.; Melendez E.; Smbatyan G.; Massiello D.; Kahn M.; Characterization of imatinib resistant CML leukemic stem\/initiating cells and their sensitivity to CBP\/catenin antagonists. Curr Mol Pharmacol  2018,11(2),113-121","journal-title":"Curr Mol Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1038\/onc.2015.438","volume":"35","author":"Zhao Y.","year":"2016","unstructured":"Zhao Y.; Masiello D.; McMillian M.; Nguyen C.; Wu Y.; Melendez E.; Smbatyan G.; Kida A.; He Y.; Teo J-L.; Kahn M.; CBP\/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells. Oncogene  2016,35(28),3705-3717","journal-title":"Oncogene"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"Giustacchini A.","year":"2017","unstructured":"Giustacchini A.; Thongjuea S.; Barkas N.; Woll P.S.; Povinelli B.J.; Booth C.A.G.; Sopp P.; Norfo R.; Rodriguez-Meira A.; Ashley N.; Jamieson L.; Vyas P.; Anderson K.; Segerstolpe \u00c5.; Qian H.; Olsson-Str\u00f6mberg U.; Mustjoki S.; Sandberg R.; Jacobsen S.E.W.; Mead A.J.; Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med  2017,23(6),692-702","journal-title":"Nat Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","volume":"129","author":"Warfvinge R.","year":"2017","unstructured":"Warfvinge R.; Geironson L.; Sommarin M.N.E.; Lang S.; Karlsson C.; Roschupkina T.; Stenke L.; Stentoft J.; Olsson-Str\u00f6mberg U.; Hjorth-Hansen H.; Mustjoki S.; Soneji S.; Richter J.; Karlsson G.; Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood  2017,129(17),2384-2394","journal-title":"Blood"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bcp.2018.11.004","volume":"162","author":"Vallette F.M.","year":"2019","unstructured":"Vallette F.M.; Olivier C.; L\u00e9zot F.; Oliver L.; Cochonneau D.; Lalier L.; Cartron P.F.; Heymann D.; Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Biochem Pharmacol  2019,162,169-176","journal-title":"Biochem Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Oren Y.","year":"2021","unstructured":"Oren Y.; Tsabar M.; Cuoco M.S.; Amir-Zilberstein L.; Cabanos H.F.; H\u00fctter J.C.; Hu B.; Thakore P.I.; Tabaka M.; Fulco C.P.; Colgan W.; Cuevas B.M.; Hurvitz S.A.; Slamon D.J.; Deik A.; Pierce K.A.; Clish C.; Hata A.N.; Zaganjor E.; Lahav G.; Politi K.; Brugge J.S.; Regev A.; Cycling cancer persister cells arise from lineages with distinct programs. Nature  2021,596(7873),576-582","journal-title":"Nature"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.3390\/cancers13225822","volume":"13","author":"Ito K.","year":"2021","unstructured":"Ito K.; Ito K.; Leukemia stem cells as a potential target to achieve therapy-free remission in chronic myeloid leukemia. Cancers  2021,13(22),5822","journal-title":"Cancers"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"Zhang B.","year":"2012","unstructured":"Zhang B.; Ho Y.W.; Huang Q.; Maeda T.; Lin A.; Lee S.; Hair A.; Holyoake T.L.; Huettner C.; Bhatia R.; Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell  2012,21(4),577-592","journal-title":"Cancer Cell"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"Zhao C.","year":"2007","unstructured":"Zhao C.; Blum J.; Chen A.; Kwon H.Y.; Jung S.H.; Cook J.M.; Lagoo A.; Reya T.; Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell  2007,12(6),528-541","journal-title":"Cancer Cell"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.2882","volume":"18","author":"Ito K.","year":"2012","unstructured":"Ito K.; Carracedo A.; Weiss D.; Arai F.; Ala U.; Avigan D.E.; Schafer Z.T.; Evans R.M.; Suda T.; Lee C.H.; Pandolfi P.P.; A PML-PPAR-\u03b4 pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med  2012,18(9),1350-1358","journal-title":"Nat Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e1098","DOI":"10.1002\/cti2.1098","volume":"8","author":"Pernes G.","year":"2019","unstructured":"Pernes G.; Flynn M.C.; Lancaster G.I.; Murphy A.J.; Fat for fuel: Lipid metabolism in haematopoiesis. Clin Transl Immunol  2019,8(12),e1098","journal-title":"Clin Transl Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature11895","volume":"494","author":"Warr M.R.","year":"2013","unstructured":"Warr M.R.; Binnewies M.; Flach J.; Reynaud D.; Garg T.; Malhotra R.; Debnath J.; Passegu\u00e9 E.; FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature  2013,494(7437),323-327","journal-title":"Nature"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41586-022-04979-5","volume":"607","author":"Rodr\u00edguez-Nuevo A.","year":"2022","unstructured":"Rodr\u00edguez-Nuevo A.; Torres-Sanchez A.; Duran J.M.; De Guirior C.; Mart\u00ednez-Zamora M.A.; B\u00f6ke E.; Oocytes maintain ROS-free mitochondrial metabolism by suppressing complex I. Nature  2022,607(7920),756-761","journal-title":"Nature"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"Stuart T.","year":"2019","unstructured":"Stuart T.; Butler A.; Hoffman P.; Hafemeister C.; Papalexi E.; Mauck W.M.; Hao Y.; Stoeckius M.; Smibert P.; Satija R.; Comprehensive integration of single-cell data. Cell  2019,177(7),1888-1902.e21","journal-title":"Cell"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1016\/j.cell.2021.05.045","volume":"184","author":"Wagner A.","year":"2021","unstructured":"Wagner A.; Wang C.; Fessler J.; DeTomaso D.; Avila-Pacheco J.; Kaminski J.; Zaghouani S.; Christian E.; Thakore P.; Schellhaass B.; Akama-Garren E.; Pierce K.; Singh V.; Ron-Harel N.; Douglas V.P.; Bod L.; Schnell A.; Puleston D.; Sobel R.A.; Haigis M.; Pearce E.L.; Soleimani M.; Clish C.; Regev A.; Kuchroo V.K.; Yosef N.; Metabolic modeling of single Th17 cells reveals regulators of autoimmunity. Cell  2021,184(16),4168-4185.e21","journal-title":"Cell"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","volume":"32","author":"Arg\u00fcello R.J.","year":"2020","unstructured":"Arg\u00fcello R.J.; Combes A.J.; Char R.; Gigan J.P.; Baaziz A.I.; Bousiquot E.; Camosseto V.; Samad B.; Tsui J.; Yan P.; Boissonneau S.; Figarella-Branger D.; Gatti E.; Tabouret E.; Krummel M.F.; Pierre P.; SCENITH: A flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metab  2020,32(6),1063-1075.e7","journal-title":"Cell Metab"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.3390\/cancers13235884","volume":"13","author":"Hu X.","year":"2021","unstructured":"Hu X.; Ono M.; Chimge N.O.; Chosa K.; Nguyen C.; Melendez E.; Lou C.H.; Lim P.; Termini J.; Lai K.K.Y.; Fueger P.T.; Teo J.L.; Higuchi Y.; Kahn M.; Differential Kat3 usage orchestrates the integration of cellular metabolism with differentiation. Cancers  2021,13(23),5884","journal-title":"Cancers"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3390\/cancers13061288","volume":"13","author":"Lai K.K.Y.","year":"2021","unstructured":"Lai K.K.Y.; Hu X.; Chosa K.; Nguyen C.; Lin D.P.; Lai K.K.; Kato N.; Higuchi Y.; Highlander S.K.; Melendez E.; Eriguchi Y.; Fueger P.T.; Ouellette A.J.; Chimge N.O.; Ono M.; Kahn M.; p300 Serine 89: A critical signaling integrator and its effects on intestinal homeostasis and repair. Cancers  2021,13(6),1288","journal-title":"Cancers"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1074\/mcp.T500039-MCP200","volume":"5","author":"Ono M.","year":"2006","unstructured":"Ono M.; Shitashige M.; Honda K.; Isobe T.; Kuwabara H.; Matsuzuki H.; Hirohashi S.; Yamada T.; Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics  2006,5(7),1338-1347","journal-title":"Mol Cell Proteomics"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e0200714","DOI":"10.1371\/journal.pone.0200714","volume":"13","author":"Ono M.","year":"2018","unstructured":"Ono M.; Lai K.K.Y.; Wu K.; Nguyen C.; Lin D.P.; Murali R.; Kahn M.; Nuclear receptor\/Wnt beta-catenin interactions are regulated via differential CBP\/p300 coactivator usage. PLoS One  2018,13(7),e0200714","journal-title":"PLoS One"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.gde.2017.11.003","volume":"48","author":"Lindqvist L.M.","year":"2018","unstructured":"Lindqvist L.M.; Tandoc K.; Topisirovic I.; Furic L.; Cross-talk between protein synthesis, energy metabolism and autophagy in cancer. Curr Opin Genet Dev  2018,48,104-111","journal-title":"Curr Opin Genet Dev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.tcb.2014.04.001","volume":"24","author":"Kohli L.","year":"2014","unstructured":"Kohli L.; Passegu\u00e9 E.; Surviving change: The metabolic journey of hematopoietic stem cells. Trends Cell Biol  2014,24(8),479-487","journal-title":"Trends Cell Biol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc3483","volume":"13","author":"Carracedo A.","year":"2013","unstructured":"Carracedo A.; Cantley L.C.; Pandolfi P.P.; Cancer metabolism: Fatty acid oxidation in the limelight. Nat Rev Cancer  2013,13(4),227-232","journal-title":"Nat Rev Cancer"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10565-016-9318-0","volume":"32","author":"Thomas P.D.","year":"2016","unstructured":"Thomas P.D.; Kahn M.; Kat3 coactivators in somatic stem cells and cancer stem cells: Biological roles, evolution, and pharmacologic manipulation. Cell Biol Toxicol  2016,32(1),61-81","journal-title":"Cell Biol Toxicol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","volume":"119","author":"Kumari A.","year":"2012","unstructured":"Kumari A.; Brendel C.; Hochhaus A.; Neubauer A.; Burchert A.; Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood  2012,119(2),530-539","journal-title":"Blood"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.2147\/CMAR.S232752","volume":"12","author":"Cumbo C.","year":"2020","unstructured":"Cumbo C.; Anelli L.; Specchia G.; Albano F.; Monitoring of Minimal Residual Disease (MRD) in chronic myeloid leukemia: Recent advances. Cancer Manag Res  2020,12,3175-3189","journal-title":"Cancer Manag Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/onc.2013.169","volume":"33","author":"Gang E.J.","year":"2014","unstructured":"Gang E.J.; Hsieh Y-T.; Pham J.; Zhao Y.; Nguyen C.; Huantes S.; Park E.; Naing K.; Klemm L.; Swaminathan S.; Conway E.M.; Pelus L.M.; Crispino J.; Mullighan C.G.; McMillan M.; M\u00fcschen M.; Kahn M.; Kim Y-M.; Small-molecule inhibition of CBP\/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene  2014,33(17),2169-2178","journal-title":"Oncogene"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2017.04.010","volume":"52","author":"Kim Y.M.","year":"2017","unstructured":"Kim Y.M.; Gang E.J.; Kahn M.; CBP\/Catenin antagonists: Targeting LSCs\u2019 achilles heel. Exp Hematol  2017,52,1-11","journal-title":"Exp Hematol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.critrevonc.2015.12.005","volume":"99","author":"Duchartre Y.","year":"2016","unstructured":"Duchartre Y.; Kim Y.M.; Kahn M.; The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol  2016,99,141-149","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.stem.2020.11.015","volume":"28","author":"Ranzoni A.M.","year":"2021","unstructured":"Ranzoni A.M.; Tangherloni A.; Berest I.; Riva S.G.; Myers B.; Strzelecka P.M.; Xu J.; Panada E.; Mohorianu I.; Zaugg J.B.; Cvejic A.; Integrative single-cell RNA-seq and ATAC-seq analysis of human developmental hematopoiesis. Cell Stem Cell  2021,28(3),472-487.e7","journal-title":"Cell Stem Cell"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1172\/JCI41624","volume":"120","author":"Bricambert J.","year":"2010","unstructured":"Bricambert J.; Miranda J.; Benhamed F.; Girard J.; Postic C.; Dentin R.; Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest  2010,120(12),4316-4331","journal-title":"J Clin Invest"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature07349","volume":"456","author":"Liu Y.","year":"2008","unstructured":"Liu Y.; Dentin R.; Chen D.; Hedrick S.; Ravnskjaer K.; Schenk S.; Milne J.; Meyers D.J.; Cole P.; Iii J.Y.; Olefsky J.; Guarente L.; Montminy M.; A fasting inducible switch modulates gluconeogenesis via activator\/coactivator exchange. Nature  2008,456(7219),269-273","journal-title":"Nature"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/14728222.2021.1992386","volume":"25","author":"Kahn M.","year":"2021","unstructured":"Kahn M.; Taking the road less traveled - the therapeutic potential of CBP\/\u03b2-catenin antagonists. Expert Opin Ther Targets  2021,25(9),701-719","journal-title":"Expert Opin Ther Targets"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"714228","DOI":"10.3389\/fgene.2021.714228","volume":"12","author":"Belser M.","year":"2021","unstructured":"Belser M.; Walker D.W.; Role of prohibitins in aging and therapeutic potential against age-related diseases. Front Genet  2021,12,714228","journal-title":"Front Genet"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.taap.2007.05.019","volume":"223","author":"Gurevich I.","year":"2007","unstructured":"Gurevich I.; Flores A.M.; Aneskievich B.J.; Corepressors of agonist-bound nuclear receptors. Toxicol Appl Pharmacol  2007,223(3),288-298","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41419-023-05575-9","volume":"14","author":"Ren L.","year":"2023","unstructured":"Ren L.; Meng L.; Gao J.; Lu M.; Guo C.; Li Y.; Rong Z.; Ye Y.; PHB2 promotes colorectal cancer cell proliferation and tumorigenesis through NDUFS1-mediated oxidative phosphorylation. Cell Death Dis  2023,14(1),44","journal-title":"Cell Death Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"Chu S.","year":"2011","unstructured":"Chu S.; McDonald T.; Lin A.; Chakraborty S.; Huang Q.; Snyder D.S.; Bhatia R.; Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood  2011,118(20),5565-5572","journal-title":"Blood"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"Ross D.M.","year":"2010","unstructured":"Ross D.M.; Branford S.; Seymour J.F.; Schwarer A.P.; Arthur C.; Bartley P.A.; Slader C.; Field C.; Dang P.; Filshie R.J.; Mills A.K.; Grigg A.P.; Melo J.V.; Hughes T.P.; Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia  2010,24(10),1719-1724","journal-title":"Leukemia"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41416-022-01787-6","volume":"126","author":"Saleh T.","year":"2022","unstructured":"Saleh T.; Gewirtz D.A.; Considering therapy-induced senescence as a mechanism of tumour dormancy contributing to disease recurrence. Br J Cancer  2022,126(10),1363-1365","journal-title":"Br J Cancer"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.immuni.2018.02.001","volume":"48","author":"Agudo J.","year":"2018","unstructured":"Agudo J.; Park E.S.; Rose S.A.; Alibo E.; Sweeney R.; Dhainaut M.; Kobayashi K.S.; Sachidanandam R.; Baccarini A.; Merad M.; Brown B.D.; Quiescent tissue stem cells evade immune surveillance. Immunity  2018,48(2),271-285.e5","journal-title":"Immunity"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"Rehman S.K.","year":"2021","unstructured":"Rehman S.K.; Haynes J.; Collignon E.; Brown K.R.; Wang Y.; Nixon A.M.L.; Bruce J.P.; Wintersinger J.A.; Singh Mer A.; Lo E.B.L.; Leung C.; Lima-Fernandes E.; Pedley N.M.; Soares F.; McGibbon S.; He H.H.; Pollet A.; Pugh T.J.; Haibe-Kains B.; Morris Q.; Ramalho-Santos M.; Goyal S.; Moffat J.; O\u2019Brien C.A.; Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell  2021,184(1),226-242.e21","journal-title":"Cell"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1046\/j.1468-0734.2001.00028.x","volume":"5","author":"Bonnet D.","year":"2001","unstructured":"Bonnet D.; Normal and leukemic CD34-negative human hematopoietic stem cells. Rev Clin Exp Hematol  2001,5(1),42-61","journal-title":"Rev Clin Exp Hematol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0301-472X(03)00051-1","volume":"31","author":"Zanjani E.D.","year":"2003","unstructured":"Zanjani E.D.; Almeida-Porada G.; Livingston A.G.; Zeng H.; Ogawa M.; Reversible expression of CD34 by adult human bone marrow long-term engrafting hematopoietic stem cells. Exp Hematol  2003,31(5),406-412","journal-title":"Exp Hematol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1046\/j.1365-2141.2003.04673.x","volume":"123","author":"Lemoli R.M.","year":"2003","unstructured":"Lemoli R.M.; Bertolini F.; Petrucci M.T.; Gregorj C.; Ricciardi M.R.; Fogli M.; Curti A.; Rabascio C.; Pandolfi S.; Ferrari S.; Fo R.; Baccarani M.; Tafuri A.; Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34  human stem cells. Br J Haematol  2003,123(4),720-729","journal-title":"Br J Haematol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nature13255","volume":"510","author":"Rodgers J.T.","year":"2014","unstructured":"Rodgers J.T.; King K.Y.; Brett J.O.; Cromie M.J.; Charville G.W.; Maguire K.K.; Brunson C.; Mastey N.; Liu L.; Tsai C.R.; Goodell M.A.; Rando T.A.; mTORC1 controls the adaptive transition of quiescent stem cells from G0 to GAlert. Nature  2014,510(7505),393-396","journal-title":"Nature"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"736758","DOI":"10.3389\/fonc.2021.736758","volume":"11","author":"Cuesta-Mateos C.","year":"2021","unstructured":"Cuesta-Mateos C.; Terr\u00f3n F.; Herling M.; CCR7 in blood cancers - Review of its pathophysiological roles and the potential as a therapeutic target. Front Oncol  2021,11,736758","journal-title":"Front Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1038\/s41375-022-01682-2","volume":"36","author":"B\u00fchrer E.D.","year":"2022","unstructured":"B\u00fchrer E.D.; Amrein M.A.; Forster S.; Isringhausen S.; Sch\u00fcrch C.M.; Bhate S.S.; Brodie T.; Zindel J.; Stroka D.; Sayed M.A.; Nombela-Arrieta C.; Radpour R.; Riether C.; Ochsenbein A.F.; Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance. Leukemia  2022,36(11),2634-2646","journal-title":"Leukemia"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41590-022-01198-y","volume":"23","author":"Li Z.","year":"2022","unstructured":"Li Z.; Ma R.; Ma S.; Tian L.; Lu T.; Zhang J.; Mundy-Bosse B.L.; Zhang B.; Marcucci G.; Caligiuri M.A.; Yu J.; ILC1s control leukemia stem cell fate and limit development of AML. Nat Immunol  2022,23(5),718-730","journal-title":"Nat Immunol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","volume":"10","author":"Heidel F.H.","year":"2012","unstructured":"Heidel F.H.; Bullinger L.; Feng Z.; Wang Z.; Neff T.A.; Stein L.; Kalaitzidis D.; Lane S.W.; Armstrong S.A.; Genetic and pharmacologic inhibition of \u03b2-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell  2012,10(4),412-424","journal-title":"Cell Stem Cell"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/emboj\/19.8.1839","volume":"19","author":"Hecht A.","year":"2000","unstructured":"Hecht A.; Vleminckx K.; Stemmler M.P.; van Roy F.; Kemler R.; The p300\/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J  2000,19(8),1839-1850","journal-title":"EMBO J"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1083\/jcb.149.2.249","volume":"149","author":"Takemaru K.I.","year":"2000","unstructured":"Takemaru K.I.; Moon R.T.; The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol  2000,149(2),249-254","journal-title":"J Cell Biol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.addr.2010.09.012","volume":"62","author":"Teo J.L.","year":"2010","unstructured":"Teo J.L.; Kahn M.; The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. Adv Drug Deliv Rev  2010,62(12),1149-1155","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"21931","DOI":"10.1073\/pnas.1016071107","volume":"107","author":"Creyghton M.P.","year":"2010","unstructured":"Creyghton M.P.; Cheng A.W.; Welstead G.G.; Kooistra T.; Carey B.W.; Steine E.J.; Hanna J.; Lodato M.A.; Frampton G.M.; Sharp P.A.; Boyer L.A.; Young R.A.; Jaenisch R.; Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci  2010,107(50),21931-21936","journal-title":"Proc Natl Acad Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"Hnisz D.","year":"2013","unstructured":"Hnisz D.; Abraham B.J.; Lee T.I.; Lau A.; Saint-Andr\u00e9 V.; Sigova A.A.; Hoke H.A.; Young R.A.; Super-enhancers in the control of cell identity and disease. Cell  2013,155(4),934-947","journal-title":"Cell"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12860-020-00296-9","volume":"21","author":"Martire S.","year":"2020","unstructured":"Martire S.; Nguyen J.; Sundaresan A.; Banaszynski L.A.; Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. BMC Mol Cell Biol  2020,21(1),55","journal-title":"BMC Mol Cell Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.tcb.2021.03.007","volume":"31","author":"Mirzadeh Azad F.","year":"2021","unstructured":"Mirzadeh Azad F.; Atlasi Y.; WNT-regulated transcriptional enhancers and stem cell plasticity. Trends Cell Biol  2021,31(7),525-528","journal-title":"Trends Cell Biol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.molcel.2019.08.016","volume":"76","author":"Zamudio A.V.","year":"2019","unstructured":"Zamudio A.V.; Dall\u2019Agnese A.; Henninger J.E.; Manteiga J.C.; Afeyan L.K.; Hannett N.M.; Coffey E.L.; Li C.H.; Oksuz O.; Sabari B.R.; Boija A.; Klein I.A.; Hawken S.W.; Spille J.H.; Decker T.M.; Cisse I.I.; Abraham B.J.; Lee T.I.; Taatjes D.J.; Schuijers J.; Young R.A.; Mediator condensates localize signaling factors to key cell identity genes. Mol Cell  2019,76(5),753-766.e6","journal-title":"Mol Cell"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"13505","DOI":"10.1074\/jbc.R000025200","volume":"276","author":"Vo N.","year":"2001","unstructured":"Vo N.; Goodman R.H.; CREB-binding protein and p300 in transcriptional regulation. J Biol Chem  2001,276(17),13505-13508","journal-title":"J Biol Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/MCB.05830-11","volume":"31","author":"Chan W.I.","year":"2011","unstructured":"Chan W.I.; Hannah R.L.; Dawson M.A.; Pridans C.; Foster D.; Joshi A.; G\u00f6ttgens B.; Van Deursen J.M.; Huntly B.J.P.; The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells. Mol Cell Biol  2011,31(24),5046-5060","journal-title":"Mol Cell Biol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/30538","volume":"393","author":"Kawasaki H.","year":"1998","unstructured":"Kawasaki H.; Eckner R.; Yao T.P.; Taira K.; Chiu R.; Livingston D.M.; Yokoyama K.K.; Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature  1998,393(6682),284-289","journal-title":"Nature"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"14789","DOI":"10.1073\/pnas.232568499","volume":"99","author":"Rebel V.I.","year":"2002","unstructured":"Rebel V.I.; Kung A.L.; Tanner E.A.; Yang H.; Bronson R.T.; Livingston D.M.; Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci  2002,99(23),14789-14794","journal-title":"Proc Natl Acad Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"12171","DOI":"10.1073\/pnas.0504600102","volume":"102","author":"Teo J.L.","year":"2005","unstructured":"Teo J.L.; Ma H.; Nguyen C.; Lam C.; Kahn M.; Specific inhibition of CBP\/\u03b2-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc Natl Acad Sci  2005,102(34),12171-12176","journal-title":"Proc Natl Acad Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"588641","DOI":"10.3389\/fonc.2020.588641","volume":"10","author":"Yang K.","year":"2021","unstructured":"Yang K.; Wang F.; Zhang H.; Wang X.; Chen L.; Su X.; Wu X.; Han Q.; Chen Z.; Chen Z.S.; Fu L.; Target inhibition of CBP induced cell senescence in BCR-ABL- T315I mutant chronic myeloid leukemia. Front Oncol  2021,10,588641","journal-title":"Front Oncol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/s41388-018-0161-z","volume":"37","author":"Zhang Y.","year":"2018","unstructured":"Zhang Y.; Wang S.; Kang W.; Liu C.; Dong Y.; Ren F.; Wang Y.; Zhang J.; Wang G.; To K.F.; Zhang X.; Sung J.J.Y.; Chang Z.; Yu J.; CREPT facilitates colorectal cancer growth through inducing Wnt\/\u03b2-catenin pathway by enhancing p300-mediated \u03b2-catenin acetylation. Oncogene  2018,37(26),3485-3500","journal-title":"Oncogene"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/blood-2010-09-307942","volume":"118","author":"Zimmer S.N.","year":"2011","unstructured":"Zimmer S.N.; Zhou Q.; Zhou T.; Cheng Z.; Abboud-Werner S.L.; Horn D.; Lecocke M.; White R.; Krivtsov A.V.; Armstrong S.A.; Kung A.L.; Livingston D.M.; Rebel V.I.; Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood  2011,118(1),69-79","journal-title":"Blood"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/iub.1366","volume":"67","author":"Bavelloni A.","year":"2015","unstructured":"Bavelloni A.; Piazzi M.; Raffini M.; Faenza I.; Blalock W.L.; Prohibitin 2: At a communications crossroads. IUBMB Life  2015,67(4),239-254","journal-title":"IUBMB Life"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"Radich J.P.","year":"2006","unstructured":"Radich J.P.; Dai H.; Mao M.; Oehler V.; Schelter J.; Druker B.; Sawyers C.; Shah N.; Stock W.; Willman C.L.; Friend S.; Linsley P.S.; Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci  2006,103(8),2794-2799","journal-title":"Proc Natl Acad Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fonc.2019.00532","volume":"9","author":"Grassi S.","year":"2019","unstructured":"Grassi S.; Palumbo S.; Mariotti V.; Liberati D.; Guerrini F.; Ciabatti E.; Salehzadeh S.; Barat\u00e8 C.; Balducci S.; Ricci F.; Buda G.; Iovino L.; Mazziotta F.; Ghio F.; Ercolano G.; Di Paolo A.; Cecchettini A.; Baldini C.; Mattii L.; Pellegrini S.; Petrini M.; Galimberti S.; The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia. Front Oncol  2019,9,532","journal-title":"Front Oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1471-2105-16-S4-S4","volume":"16","author":"Taskesen E.","year":"2015","unstructured":"Taskesen E.; Staal F.J.T.; Reinders M.J.T.; An integrated approach of gene expression and DNA-methylation profiles of WNT signaling genes uncovers novel prognostic markers in Acute Myeloid Leukemia. BMC Bioinform  2015,16(S4),S4","journal-title":"BMC Bioinform"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/sj.leu.2404239","volume":"20","author":"Ysebaert L.","year":"2006","unstructured":"Ysebaert L.; Chicanne G.; Demur C.; De Toni F.; Prade-Houdellier N.; Ruidavets J-B.; Mansat-De Mas V.; Rigal-Huguet F.; Laurent G.; Payrastre B.; Manenti S.; Racaud-Sultan C.; Expression of \u03b2-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia  2006,20(7),1211-1216","journal-title":"Leukemia"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/sj.leu.2404732","volume":"21","author":"Mikesch J-H.","year":"2007","unstructured":"Mikesch J-H.; Steffen B.; Berdel W.E.; Serve H.; M\u00fcller-Tidow C.; The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia  2007,21(8),1638-1647","journal-title":"Leukemia"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"12682","DOI":"10.1073\/pnas.0404875101","volume":"101","author":"Emami K.H.","year":"2004","unstructured":"Emami K.H.; Nguyen C.; Ma H.; Kim D.H.; Jeong K.W.; Eguchi M.; Moon R.T.; Teo J.L.; Kim H.Y.; Moon S.H.; Ha J.R.; Kahn M.; A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription. Proc Natl Acad Sci  2004,101(34),12682-12687","journal-title":"Proc Natl Acad Sci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/cancers11070962","volume":"11","author":"Lukaszewicz A.I.","year":"2019","unstructured":"Lukaszewicz A.I.; Nguyen C.; Melendez E.; Lin D.P.; Teo J.L.; Lai K.K.Y.; Huttner W.B.; Shi S.H.; Kahn M.; The mode of stem cell division is dependent on the differential interaction of \u03b2-Catenin with the Kat3 coactivators CBP or p300. Cancers  2019,11(7),962","journal-title":"Cancers"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/cancers10040095","volume":"10","author":"Manegold P.","year":"2018","unstructured":"Manegold P.; Lai K.; Wu Y.; Teo J.L.; Lenz H.J.; Genyk Y.; Pandol S.; Wu K.; Lin D.; Chen Y.; Nguyen C.; Zhao Y.; Kahn M.; Differentiation therapy targeting the \u03b2-Catenin\/CBP interaction in pancreatic cancer. Cancers  2018,10(4),95","journal-title":"Cancers"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/220758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220758\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/220758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:58:43Z","timestamp":1746557923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220758\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":87,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467217666230906092236","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e060923220758"}}